Lens (anatomy)

The American Optometric Association Issues Consumer Health Alert for Online Vision Tests

Retrieved on: 
Thursday, October 27, 2022

ST. LOUIS, Oct. 27, 2022 /PRNewswire/ --Today, the American Optometric Association (AOA) issued a consumer health alert to guide the public on key questions that individuals should ask when considering the use of online vision tests.

Key Points: 
  • ST. LOUIS, Oct. 27, 2022 /PRNewswire/ --Today, the American Optometric Association (AOA) issued a consumer health alert to guide the public on key questions that individuals should ask when considering the use of online vision tests.
  • "The AOA takes seriously our role in providing accurate information regarding eye health and vision care to the American public," says AOA President Robert C. Layman, O.D.
  • For more information on eye health and vision, or to find a local AOA doctor of optometry, visit AOA.org.
  • The American Optometric Association (AOA) is the leading authority on and advocate for quality eye health care, representing more than 44,000 doctors of optometry, optometry students and optometric professionals.

Alignment Health Plan Recognized as Best Insurance Company for Medicare Advantage in North Carolina by U.S. News & World Report

Retrieved on: 
Monday, October 24, 2022

RALEIGH, N.C. and ORANGE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Alignment Health Plan, an award-winning Medicare Advantage (MA) insurance carrier from Alignment Health, has been named a 2023 Best Insurance Company for Medicare Advantage plans by U.S. News & World Report for its top-rated HMO in North Carolina.

Key Points: 
  • RALEIGH, N.C. and ORANGE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Alignment Health Plan, an award-winning Medicare Advantage (MA) insurance carrier from Alignment Health, has been named a 2023 Best Insurance Company for Medicare Advantage plans by U.S. News & World Report for its top-rated HMO in North Carolina.
  • Alignment is one of only four MA insurance companies in the state to earn the U.S. News Best rankings badge .
  • Alignment Health Plan is honored to be named a Best Insurance Company for Medicare Advantage plans by U.S. News & World Report, said Dawn Maroney, CEO of Alignment Health Plan.
  • Alignment Health has worked with various Medicare Advantage carriers in North Carolina since 2014 and introduced its own Alignment Health Plan coverage to the state in 2021, the year on which the 2023 rating is based.

Alcon to Celebrate 75 Years of Brilliance and Showcase Contact Lens Innovations at #Academy22

Retrieved on: 
Wednesday, October 26, 2022

The meeting coincides with Alcons Diamond Jubilee, celebrating 75 years of helping people see brilliantly.

Key Points: 
  • The meeting coincides with Alcons Diamond Jubilee, celebrating 75 years of helping people see brilliantly.
  • Alcon will host an engaging on-site program featuring events and the latest clinical presentations across contact lenses, allergy, dry eye and more.
  • In 2023, Alcon will expand its MARLO services to provide patients with greater access to eye care.
  • A02491-REP-198231-1 Outermost Surface Softness Analysis of lehfilcon A Contact Lenses and Correlation with Water Content Based upon Petrisoft Gels.

Johnson & Johnson Vision Reveals New Data on Blue-Violet Light Filtering Technology in ACUVUE® OASYS MAX 1-DAY Contact Lenses

Retrieved on: 
Wednesday, October 26, 2022

Academy attendees in San Diego can visit the Johnson & Johnson Vision Booth #1117, to learn more about the technology used in ACUVUEOASYS MAX 1-Day contact lenses.

Key Points: 
  • Academy attendees in San Diego can visit the Johnson & Johnson Vision Booth #1117, to learn more about the technology used in ACUVUEOASYS MAX 1-Day contact lenses.
  • At Johnson & Johnson Vision, part of Johnson & Johnson MedTech, we have a bold ambition: to change the trajectory of eye health around the world.
  • Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
  • Material Properties: 1-DAY ACUVUE MOIST, 1-DAY ACUVUE TruEye, ACUVUE OASYS 1-Day with HydraLuxe Technology and ACUVUE OASYS MAX 1-Day with TearStable Technology Brand Contact Lenses.

Eye Safety Tips to Keep Halloween From Getting Really Scary

Retrieved on: 
Tuesday, October 25, 2022

PITTSBURGH, Oct. 25, 2022 /PRNewswire/ -- An eye infection, injury, or accident could make Halloween really scary.

Key Points: 
  • PITTSBURGH, Oct. 25, 2022 /PRNewswire/ -- An eye infection, injury, or accident could make Halloween really scary.
  • Halloween costumes are fun and everyone wants to make a big "visual" impression, but here are tips from Safe Eyes America to keep you and your eyes safe.
  • BEWARE Your vision this Halloween is at risk if you or your teenager plan to wear costume contact lenses sold without a prescription.
  • Although the sale of non-prescription contact lenses is illegal, they are sometimes found at costume shops, drug stores or online.

Bausch + Lomb Introduces Project Watson™ Health Care Products for Dogs

Retrieved on: 
Monday, October 24, 2022

VAUGHAN, ON, Oct. 24, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the introduction of Project Watson health care products for dogs in the United States. The new line of products is specifically formulated to help support dogs' eyes, ears and overall wellbeing using high quality and naturally inspired ingredients.  

Key Points: 
  • New Products Will Focus on Dogs' Eyes, Ears and Overall Wellbeing
    VAUGHAN, ON, Oct. 24, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the introduction of Project Watson health care products for dogs in the United States.
  • Building on our eye care expertise and history in surgical solutions for veterinarians, we created Project Watson to help address the unmet health care needs of dogs," said Joe Gordon, president, Global Consumer, Surgical and Vision Care, Bausch + Lomb.
  • This led to the development of Project Watson health care products for dogs that are specifically formulated with the same expert care and unwavering quality as all other products in the Bausch + Lomb portfolio.
  • With the availability of Project Watson products in the United States, Bausch + Lomb is focused on ensuring dogs can receive the care they need.

Innovega Signs Smart Glasses Letter of Intent with Global Electronics Supplier

Retrieved on: 
Thursday, October 20, 2022

Innovega selected this company for its unique ability to design and manufacture precision components needed to deliver the quality of smart glasses designed for comfort and performance.

Key Points: 
  • Innovega selected this company for its unique ability to design and manufacture precision components needed to deliver the quality of smart glasses designed for comfort and performance.
  • This is Innovegas second Letter of Intent for evaluating opportunities for its next-generation display eyewear that is protected by 69 filed patent cases.
  • Our product licensing model for Innovegas smart contact lenses and smart glasses allows the Innovega team to remain focused on delivering world-class innovation.
  • Innovegas display system includes patented disposable soft smart contact lenses that are used in conjunction with its smart display glasses.

Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia

Retrieved on: 
Thursday, October 20, 2022

VISION-2 is the fourth Phase 3 study demonstrating the utility of the companys MAP technology in improving the therapeutic index of topical ophthalmic drugs.

Key Points: 
  • VISION-2 is the fourth Phase 3 study demonstrating the utility of the companys MAP technology in improving the therapeutic index of topical ophthalmic drugs.
  • We are very pleased with these Phase 3 study results which again demonstrate the benefits of our proprietary Optejet device that underpins MicroLine as a potential on-demand treatment for presbyopia, stated Michael Rowe, Chief Executive Officer of Eyenovia.
  • We look forward to meeting with the FDA within our planned commercialization timeline in preparation for a potential new drug application (NDA) submission.
  • The VISION-2 study was a double-masked, placebo-controlled, cross-over superiority trial in which 140 subjects with presbyopia were treated.

STAAR Surgical to Report Third Quarter Results on November 2, 2022

Retrieved on: 
Wednesday, October 19, 2022

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended September 30, 2022 on Wednesday, November 2, 2022 after the market close.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended September 30, 2022 on Wednesday, November 2, 2022 after the market close.
  • STAAR will host a conference call and webcast on Wednesday, November 2 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress.
  • To access the conference call (Access Code 976076), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants.
  • The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .

LENZ Therapeutics Announces Positive Topline Data from Phase 2 INSIGHT Trial of LNZ100 and LNZ101 to Treat Presbyopia

Retrieved on: 
Tuesday, October 18, 2022

LENZ Therapeutics, a privately held late-stage clinical company, today reported positive topline results from its Phase 2 INSIGHT clinical trial of two investigational formulations of aceclidine to treat presbyopia.

Key Points: 
  • LENZ Therapeutics, a privately held late-stage clinical company, today reported positive topline results from its Phase 2 INSIGHT clinical trial of two investigational formulations of aceclidine to treat presbyopia.
  • Based on these positive outcomes, the company plans to initiate Phase 3 trials shortly.
  • In conjunction with establishing these positive results, the company intends to initiate Phase 3 pivotal trial shortly.
  • Its lead programs, LNZ100 and LNZ101, are aceclidine-based eye drops designed to restore the loss of near vision associated with presbyopia.